3 Sleep Scientists Make 2023 Nobel Prize Predictions List
Clarivate has named three sleep scientists as 2023 Citation Laureates, researchers whose work is deemed to be of Nobel class.
Category: Narcolepsy
Narcolepsy
Latest
Narcolepsy
Latest
Centessa to Present Preclinical Data for Investigational Orexin Agonist for Narcolepsy
Centessa Pharmaceuticals reported second-quarter highlights, spotlighting progress for ORX750, an oral selective orexin-2 receptor agonist in development for narcolepsy and other sleep disorders.
Narcolepsy
Latest
How to Navigate the Narcolepsy Pharmacotherapy Landscape
With new narcolepsy drugs available—and more in the pipeline—sleep specialists face the challenge of selecting the most suitable therapies for their patients.
Harmony Biosciences Names Recipients of Patients and Progress at the Heart Awards
Harmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address challenges facing people living with sleep disorders and rare neurological diseases.
Read MoreNarcolepsy Awareness Gets Boost with Premiere of New PSA
Wake Up Narcolepsy premiered a new narcolepsy public service announcement in partnership with Red Square Pictures, aiming to depict narcolepsy accurately.
Read More
Pupil Size Provides Insight into Orexin Neuron Activity
In the future, examining pupil size could help more precisely research the influence of orexin on conditions like narcolepsy—and possibly even simplify and improve diagnosis.
Read More
Phase 3 Trial of Mazindol ER for Narcolepsy to Begin
The AMAZE program, commencing this summer at multiple sites in the US, will encompass two almost-identical double-blind phase 3 studies investigating mazindol ER versus placebo in adult patients with narcolepsy.
Read More
Xyrem Generic for Narcolepsy Launches in US
Sodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read More
Pitolisant Receives Approval in China for Narcolepsy Treatment
The approval makes pitolisant the first and only treatment drug approved in mainland China for narcolepsy.
Read More
Physician Discovers Surprising Possible Side Effect of Xywav in Narcolepsy Patient
A patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read More
Mazindol Demonstrates Low Risk for Drug Interactions in Narcolepsy Treatment
Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd announced positive data from five in vitro drug-drug interaction studies investigating mazindol.
Read More
Survey Highlights Clinician Preference for Once-at-Bedtime Oxybate for Narcolepsy
The study, funded by Avadel Pharmaceuticals, describes clinician preferences among oxybate treatments for narcolepsy.
Read More
Avadel Announces US Launch of Lumryz for Narcolepsy
After receiving FDA approval last month, Lumryz, a once-nightly formulation of sodium oxybate, is now commercially available for adults with narcolepsy.
Read More
Axsome to Present New Sunosi Data at SLEEP 2023
The presentations include data from the SHARP study in patients with excessive daytime sleepiness associated with OSA, real-world data from OSA patients taking Sunosi as part of the SURWEY study in Germany, healthcare resource use in OSA patients with residual EDS, and effect sizes and numbers needed to treat analyses.
Read More
Eisai to Present Latest Data on Lemborexant at SLEEP 2023
Tokyo-based Eisai will present eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (Dayvigo) at SLEEP 2023.
Read More
Avadel to Unveil New Data on Lumryz for Narcolepsy Treatment
Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.
Read More
Jazz to Present Seven Abstracts on Idiopathic Hypersomnia and Narcolepsy
Jazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read More
Patient-Led Initiative to Propel Development of Sleep Disorder Treatments
The program will provide researchers with the opportunity to request and analyze high-quality data and enable individuals with primary central disorders of hypersomnolence to share their data.
Read More